Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: Implications for targeted EZH2 inhibitor therapy?

5 Feb 2015

Abstract excerpt

// Sydney Dubois 1 , Sylvain Mareschal 1 , Jean-Michel Picquenot 1, 2 , Pierre-Julien Viailly 1 , Elodie Bohers 1 , Marie Cornic 2 , Philippe Bertrand 1 , Elena Liana Veresezan 1, 2 , Philippe Ruminy 1 , Catherine Maingonnat 1 , Vinciane Marchand 1 , Hélène Lanic 1, 3 , Dominique Penther 1 , Christian Bastard 1 , Hervé Tilly 1, 3 , Fabrice Jardin 1, 3 1 INSERM U918, Centre Henri Becquerel, Université de Rouen,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related gene regulation
Share to Epigenetics and DNA Methylation
Share to Lymphoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25762637
DOI: 10.18632/oncotarget.3154

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: Implications for targeted EZH2 inhibitor therapy?PMID 25762637Read ↗

A Cohort Study of the Prognostic Impact of Exon-16 EZH2 Mutations in a Mexican-Mestizo Population of Patients with Diffuse Large B-Cell Lymphoma.Semantic proximity Read ↗

Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapySemantic proximity Read ↗

Primary Bone Diffuse Large B-cell Lymphoma (PB-DLBCL) – a distinct extranodal lymphoma of germinal center origin, with an EZB-like mutational profile and good prognosisSemantic proximity Read ↗

Activating somatic mutations in diffuse large B-cell lymphomas: lessons from next generation sequencing and key elements in the precision medicine era.Semantic proximity Read ↗

Evolving insights into the genomic complexity and immune landscape of diffuse large B-cell lymphoma: opportunities for novel biomarkers.Semantic proximity Read ↗

Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assaySemantic proximity Read ↗

Genetic heterogeneity of DLBCL, not otherwise specified.Semantic proximity Read ↗

Are We Ready To Stratify Treatment for Diffuse Large B-Cell Lymphoma Using Molecular Hallmarks?Semantic proximity Read ↗

A Promising Future for Precision Epigenetic Therapy for Follicular and Diffuse Large B-Cell Lymphoma?Semantic proximity Read ↗

Activating mutations affecting the NF-kappa B pathway and EZH2-mediated epigenetic regulation are rare events in primary mediastinal large B-cell lymphoma.Semantic proximity Read ↗

Prevalence of targetable oncogenic mutations and genomic alterations in Epstein-Barr virus-associated diffuse large B-cell lymphoma of the elderly.Semantic proximity Read ↗

Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.